News

Preventing hospital readmissions must be top of mind for payers and providers, says Jill Duncan, RN, executive director at the Institute for Healthcare Improvement, where she leads the Joint Replacement Learning Community.

Successful healthcare systems share their strategies for reducing hospital readmissions.

Studies have found that getting diabetes under control early on has immediate benefits. Here’s how providers and patients can more proactively address the disease.

Specific benefits patients with diabetes have experienced due to the ACA, and how those benefits are impacting diabetes costs.

FDA recently granted accelerated approval for atezolizumab (Tecentriq, Genentech), the first drug for bladder cancer that utilizes the body’s immune system. The drug will be available by early June.

At the ASCO 2016 Annual Meeting, an expert from the Moffitt Cancer Center will discuss use of genetics to guide targeted-therapies and immunotherapies.

A value-based cancer care model focuses on better aligning providers with health plans and employers through an IPA.

The ACA risk-adjustment model applies to plans sold in the individual and small group commercial market, including plans sold through exchange marketplaces. Here are four main limitations.

Probuphine implant could be a new option for addicts if obstacles, such as price, don’t get in the way.

FDA has approved lenvatinib (Lenvima, Eisai Inc.) in combination with everolimus for the treatment of advanced renal cell carcinoma.

In alarming news for diabetic patients taking canagliflozin (Invokana, Invokamet) medications, FDA is warning that interim safety results from an ongoing clinical trial found an increase in foot and leg amputations with the drugs.

Although the diabetes pipeline is not large, we continue to have progress in meeting the unmet needs of patients with diabetes.

CMS’ Comprehensive Care for Joint Replacement model will hold hospitals financially responsible for the quality and cost of hip and knee replacements.

Participants in a new CMS payment program will attempt to improve the effectiveness and efficiency of cancer care delivery. Here’s how.

Researchers from Leavitt Partners are using a combination of public and proprietary data to report on some early findings about ACOs.

The industry is awaiting the Supreme Court’s ruling on Universal Health Services v. Escobar. This case concerns the viability of the “implied certification” theory of legal falsity under the False Claims Act.

The combination of unsustainable healthcare spending and the rapid growth of value-based reimbursement revenue models is driving the shift to patient-centered care across the continuum-or continuum-centered care.

Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here’s how. Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here's how.

A look at some of the technology advances at one hospital, and across the country, that are changing the way pediatric cancer patients are treated.

Healthcare organizations are looking for new ways to engage consumers, streamline information sharing and transparency and collaborate with other industry stakeholders. As a result, healthcare stakeholders need to focus on three key strategies.

Nivolumab (Opdivo, Bristol-Myers Squibb) received two new approvals from FDA to treat two different cancers.

How approaching the open-enrollment process with a customer-centric mindset promotes member retention.

After heavy criticism by Congress, presidential candidates and others, Valeant Pharmaceuticals is offering a discount program on its heart drugs Nitropress and Isuprel.

There's a growing need for improved access to medication-assisted treatment among patients with opioid use disorder, according to a new study presented at the American Society of Addiction Medicine 47th Annual Conference.

If a proposed Vermont bill is successful, drug companies would have to explain why they hiked prices on certain drugs.

A recent survey reveals how generational differences affect consumers’ health plan and provider preferences and selections.

Creating a national data policy framework for empowered consumer choices.

With new requirements from CMS on the horizon, how will the shift to value-based care impact consumers, payers, and providers?

FDA issued a new warning about potentially serious side effects associated with fluoroquinolone antibacterial drugs. Affected brands include Cipro, Levaquin, Avelox, Factive and Moxaflaxacin injection, as well as the generic Ofloxacin.

As pharmaceutical companies of all sizes continue to adapt to the ongoing internal and external pressures of the new health economy, it remains imperative that strategy maintain distinct capabilities to position the company ahead of its competitors.